Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALADE phase 3 study of acalabrutinib plus R-CHOP versus placebo plus R-CHOP in previously untreated non-GCB diffuse large B-cell lymphoma
jRCT2041200065Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Acalabrutinib + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Progression-free survival. Started Jan 2021; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2041200065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200065.